LAZERTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 44 adverse event reports in the FDA FAERS database where LAZERTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for LAZERTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 77 | 21.9% | 0 | 3 |
| Neuropathy peripheral | 32 | 9.1% | 0 | 0 |
| Infusion related reaction | 30 | 8.5% | 1 | 6 |
| Fatigue | 26 | 7.4% | 2 | 4 |
| Diarrhoea | 20 | 5.7% | 0 | 4 |
| Off label use | 19 | 5.4% | 0 | 5 |
| Paronychia | 16 | 4.6% | 0 | 1 |
| Pruritus | 13 | 3.7% | 0 | 0 |
| Nausea | 12 | 3.4% | 1 | 2 |
| Dyspnoea | 11 | 3.1% | 1 | 2 |
| Oedema peripheral | 11 | 3.1% | 0 | 4 |
| Hypoaesthesia | 10 | 2.8% | 0 | 1 |
| Stomatitis | 10 | 2.8% | 0 | 1 |
| Decreased appetite | 9 | 2.6% | 0 | 0 |
| Non-small cell lung cancer | 9 | 2.6% | 1 | 1 |
Other Indications for LAZERTINIB
Non-small cell lung cancer (133)
Product used for unknown indication (114)
Non-small cell lung cancer metastatic (16)
Egfr gene mutation (12)
Lung adenocarcinoma stage iv (6)
Lung carcinoma cell type unspecified recurrent (5)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)